AZ’s new cancer drugs drive another stellar quarter

ESMO 2019 – new data could unlock bigger market for PARP inh...

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian...

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.

AZ/MSD’s Lynparza sees positive results in prostate cancer

AstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian c...